In HR+ BC, CDK 4/6 inhibitor, mTOR inhibitor, and PI3K/AKT inhibitor have expanded therapeutic options for HR+ BC and delayed the initiation of chemotherapy [3,4,5,6,7,8]. Here, AKT1 is linked to breast cancer.